lacutamab   Click here for help

GtoPdb Ligand ID: 14662

Synonyms: IPH-4102 | IPH4102
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lacutamab (IPH4102) is a humanized anti-KIR3DL2, cytotoxicity-inducing, monoclonal antibody [3-4,6].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Lacutamab (IPH4102) was progressed as a clinical candidate, principally as a treatment for cutaneous T-cell lymphomas (CTCL) that commonly expresse KIR3DL2 [2,4,6]. IPH4102 was granted orphan drug status in the European Union and in the United States for the treatment of CTCL, and in January 2019 received FDA fast track designation for Sézary syndrome, to expedite its development and regulatory review in this patient subset (based on preliminary Phase I results that demonstrated significant clinical activity [5]).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05321147 Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 Phase 1 Interventional Innate Pharma
NCT03902184 IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma Phase 2 Interventional Innate Pharma
NCT02593045 Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Phase 1 Interventional Innate Pharma 1